Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 285-289

  Speidl, Walter S ^a   Katsaros, Katharina M ^a   Kastl, Stefan P ^a   Zorn, Gerlinde ^a   Huber, Kurt ^b   Maurer, Gerald ^a   Wojta, Johann ^a   Christ, Günter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Complement; Drug eluting stent; Percutaneous coronary intervention; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOPATHOGENESIS; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

AGED; COMPLEMENT C3A; COMPLEMENT C5A; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 73449102119     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.07.030     Document Type: Article

References (36)

1. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 49 (2007) 2320-2328
2. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., and Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
3. Wiskirchen J., Schober W., Schart N., et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol 39 (2004) 565-571
4. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
5. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
6. Schulman E.S., Post T.J., Henson P.M., and Giclas P.C. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 81 (1988) 918-923
7. Nataf S., Davoust N., Ames R.S., Barnum S.R., and Human. T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 162 (1999) 4018-4023
8. Foreman K.E., Vaporciyan A.A., Bonish B.K., et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 94 (1994) 1147-1155
9. Okusawa S., Yancey K.B., van der Meer J.W., et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 168 (1988) 443-448
10. Bokisch V.A., Muller-Eberhard H.J., and Cochrane C.G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129 (1969) 1109-1130
11. Oksjoki R., Laine P., Helske S., et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 195 (2007) 90-99
12. Speidl W.S., Exner M., Amighi J., et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 26 (2005) 2294-2299
13. Speidl W.S., Exner M., Amighi J., et al. Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty. J Endovasc Ther 14 (2007) 62-69
14. Kowalski J., Kosmider M., Pawlicki L., et al. Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. Int J Cardiol 58 (1997) 229-240
15. Pasqui A.L., Di Renzo M., Bova G., et al. Changes of some immune functions after percutaneous transluminal coronary angioplasty (PTCA). Int J Clin Pharmacol Res 15 (1995) 139-144
16. Katsaros K.M., Speidl W.S., Kastl S.P., et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 6 (2008) 508-513
17. Ryan T.J., Faxon D.P., Gunnar R.M., et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78 (1988) 486-502
18. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 11 (1990) 116-128
19. Welt F.G., and Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22 (2002) 1769-1776
20. Colombo A., and Sangiorgi G. The monocyte: the key in the lock to reduce stent hyperplasia?. J Am Coll Cardiol 43 (2004) 24-26
21. Hojo Y., Ikeda U., Katsuki T., et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84 (2000) 83-87
22. Cipollone F., Marini M., Fazia M., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
23. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 82 (1998) 515-518
24. Walter D.H., Fichtlscherer S., Sellwig M., Auch-Schwelk W., Schachinger V., and Zeiher A.M. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37 (2001) 839-846
25. Dibra A., Mehilli J., Braun S., et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 150 (2005) 344-350
26. Dibra A., Ndrepepa G., Mehilli J., et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 95 (2005) 1238-1240
27. de la Torre-Hernandez J.M., Sainz-Laso F., Burgos V., et al. Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. Am J Cardiol 95 (2005) 748-751
28. Park D.W., Lee C.W., Yun S.C., et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 93 (2007) 1087-1092
29. Kastrati A., Schomig A., Elezi S., et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 100 (1999) 1285-1290
30. Kastrati A., Dibra A., Mehilli J., et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113 (2006) 2293-2300
31. Khattab A.A., Hamm C.W., Senges J., et al. Prognostic value of the modified american college of cardiology/american heart association lesion morphology classification for clinical outcome after sirolimus-eluting stent placement (results of the prospective multicenter german cypher registry). Am J Cardiol 101 (2008) 477-482
32. Hayashida K., Tanaka M., Morita H., et al. Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty. Heart Vessels 16 (2002) 137-145
33. Neumann F., Kastrati A., Miethke T., et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357 (2001) 2085-2089
34. Schiele F., Batur M.K., Seronde M.F., et al. Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study. Heart 85 (2001) 304-311
35. Tanaka T., Matsushita M., Oka Y., Sada T., and Kira Y. Effect of Chlamydia pneumoniae infection on coronary flow reserve and intimal hyperplasia after stent implantation in patients with angina pectoris. J Cardiol 38 (2001) 311-317
36. Zairis M.N., Papadaki O.A., Psarogianni P.K., et al. Serologic markers of persistent Chlamydia pneumonia infection and long-term prognosis after successful coronary stenting. Am Heart J 146 (2003) 1082-1089